Proteomics

Dataset Information

0

Quantitative proteomics in osteoblasts-released matrix vesicles


ABSTRACT: The use of glycosaminoglycan-coated implants are a promising therapeutic approach in bone research since they mimic the native bone environment and facilitate the skeletonegenesis. Previous studies showed that sulfated glycosaminoglycans induce the osteoblastic phenotype, but the overall effect on the cellular proteome were only minor. Therefore we focussed on the osteoblast-released matric vesicles (MV) that are known to hold a keyrole in the initiation of the mineralization of the extracellular matrix. Indeed, we found a strong impact of sulfated glycosaminoglycans on the activity and composition of MV. In addition, to find out if the altered MV composition is a reflection of an altered cellular proteome we compared the GAG-induced changes in both proteome.

INSTRUMENT(S): LTQ Orbitrap XL

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Osteoblast, Bone Marrow

SUBMITTER: Johannes R. Schmidt  

LAB HEAD: Martin von Bergen

PROVIDER: PXD002498 | Pride | 2015-11-30

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
RAW-Matrix_vesicle.zip Other
RAW-cells.zip Other
SEARCH-Matrix_vesicle.zip Other
SEARCH-cells.zip Other
apl_files_MV_data_set.zip Other
Items per page:
1 - 5 of 8
altmetric image

Publications

Osteoblast-released Matrix Vesicles, Regulation of Activity and Composition by Sulfated and Non-sulfated Glycosaminoglycans.

Schmidt Johannes R JR   Kliemt Stefanie S   Preissler Carolin C   Moeller Stephanie S   von Bergen Martin M   Hempel Ute U   Kalkhof Stefan S  

Molecular & cellular proteomics : MCP 20151123 2


Our aging population has to deal with the increasing threat of age-related diseases that impair bone healing. One promising therapeutic approach involves the coating of implants with modified glycosaminoglycans (GAGs) that mimic the native bone environment and actively facilitate skeletogenesis. In previous studies, we reported that coatings containing GAGs, such as hyaluronic acid (HA) and its synthetically sulfated derivative (sHA1) as well as the naturally low-sulfated GAG chondroitin sulfate  ...[more]

Similar Datasets

2019-03-15 | PXD009434 | Pride
2020-09-21 | PXD021263 | Pride
2021-11-03 | PXD023362 | Pride
2013-12-23 | GSE48907 | GEO
| PRJNA1081917 | ENA
2022-02-17 | PXD028982 | Pride
2021-06-24 | GSE178558 | GEO
2021-06-24 | GSE178548 | GEO
2015-07-23 | E-GEOD-71228 | biostudies-arrayexpress
2021-01-17 | GSE145462 | GEO